Key facts, as of
As of October 11, 2026, AbbVie Inc. (ABBV) trades at $276.47, up 19.8% over the past year. It is at the top of its 52-week range ($190.75 to $277.60). It trades within 0.5% of its all-time high of $277.60, set in October 2026. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +525.2%, against +312.9% for the S&P 500 (SPY). It sits 18.8% above its 200-day average of $232.65, the usual sign of a long-term uptrend. Its 30-day volatility is 12.1% annualized, which we rate low risk. It has a trailing P/E of 78.1 and a dividend yield of 2.50%.
Cite: Portfolio Terminal, "AbbVie Inc. (ABBV) stock analysis", 2026-10-11. https://portfolio-terminal.com/analyse/abbv
Where it trades today
trading 99% of the way up its 52-week range
How the price has moved
How far it is from its record
AbbVie Inc. (ABBV) trades within 0.5% of its all-time high of $277.60, set in October 2026. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +525.2%, against +312.9% for the S&P 500 (SPY).
What to weigh before acting
What Matters Now
- The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
- ABBV trades at 78.1x earnings, well above the healthcare average of 22.0x, so the market is already pricing in above-consensus execution.
- Recent realized volatility sits near 12.1%, below the sector norm of 22.0%, which supports a steadier role inside a diversified portfolio.
- ABBV is in a bullish short-term regime and only 0.4% below its 52-week high, so the question is whether fundamentals can keep pace with that stronger tape.
Portfolio Use Case
- ABBV is more relevant for investors who want some income support alongside price appreciation, not just pure growth exposure.
- The beta profile suggests it can fit a quality or lower-volatility sleeve more naturally than a high-octane tactical basket.
- The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.
What Would Change the View
- A reset in earnings expectations or a faster peer catch-up could compress the premium valuation currently embedded in ABBV.
- If the short-term trend rolls over while volume fades, the market may stop paying up for momentum before the fundamentals change.
- The view would need revisiting if peers such as UNH, JNJ, PFE start winning the marginal flow or posting cleaner operating momentum.
Methodology
- Price, market cap, beta, yield, and liquidity fields for ABBV come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, JNJ, PFE.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for ABBV. Last refresh: Oct 11, 2026, 11:16 PM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as UNH, JNJ, PFE.
What AbbVie Inc. does
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands;…
Employees
57,000
Industry
Drug Manufacturers - General
Headquarters
North Chicago, United States
What analysts expect
ABBV carries a buy consensus from 28 analysts, with an average price target of $282.61 versus $276.47 today (+2.2%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
ABBV generated $64.39B in trailing revenue (10.2% year over year), with a 9.8% net margin, and $16.87B of free cash flow, against $64.32B of net debt.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $61.16B | $42.96B | $20.09B | $4.23B | $2.39 | $17.82B |
| 2024 | $56.33B | $39.43B | $11.89B | $4.28B | $2.42 | $17.83B |
| 2023 | $54.32B | $33.90B | $13.54B | $4.86B | $2.75 | $22.06B |
| 2022 | $58.05B | $40.64B | $18.81B | $11.84B | $6.69 | $24.25B |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
Which ETFs hold it
ABBV is in 9 of the 30 ETFs we track. It weighs most in XLV: 7.59% of the fund, holding #3 of 62.
How it sits in healthcare
Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.
The companies it competes with
ABBV beside the healthcare names it is usually measured against.
What the chart is saying
Trading at its high for the year, with no resistance overhead.
uptrend- Price is 6.8% above its 50-day average and 18.8% above its 200-day.
- The 50-day crossed above the 200-day on 2026-07-09 (a “golden cross”).
- RSI at 71 is overbought: strong momentum, and stretched.
- Nothing above has stopped it this year; the nearest floor is $267.02 (-3.4%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
Is ABBV a good investment in 2026?
AbbVie Inc. trades at a P/E ratio of 78.1, with low volatility (12.1% annualized). Recent momentum is positive.
What is the risk level of ABBV?
Based on 30-day volatility of 12.1%, ABBV has LOW risk. Beta of 0.23 indicates lower sensitivity to market movements than average.
Does ABBV pay dividends?
Yes, AbbVie Inc. has a dividend yield of 2.50%.
How far is ABBV from its all-time high?
AbbVie Inc. trades within 0.5% of its all-time high of $277.60, set in October 2026. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +525.2%, against +312.9% for the S&P 500 (SPY).
Which ETFs hold ABBV?
9 of the 30 popular ETFs we track hold AbbVie Inc.. The largest weights: XLV (7.59%), VIG (1.93%), VYM (1.82%), JEPI (1.70%) and VTV (1.65%). Measured on each issuer's full holdings file, dated August 31 to September 24, 2026.
How much of VOO is ABBV?
0.68%, as of August 31, 2026: ABBV is holding #20 of 505 in Vanguard's file for VOO. $1,000 in VOO puts about $6.85 in AbbVie Inc..
What is the analyst price target for ABBV?
The average analyst price target for AbbVie Inc. (ABBV) is $282.61 based on 28 analyst estimates, about 2.2% above the current price of $276.47. The published range runs from $200.00 to $328.00.
How much revenue does ABBV generate?
AbbVie Inc. reported $64.39B in trailing twelve-month revenue. Revenue growth is running at 10.2% year over year. Net margin sits at 9.8%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare ABBV with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.